A randomised clinical trial was conducted to establish the effects of oral and intramuscular administration of vitamin K at birth on plasma concentrations ofvitamin K1, proteins induced by vitamin K absence (PIVKA-II), and clotting factors. Two groups of about 165 healthy breast fed infants who received at random 1 mg vitamin K1 orally or intramuscularly after birth were studied at 2 weeks and 1 and 3 months of age. Although vitamin K1 concentrations were statistically significantly higher in the intramuscular group, blood coagulability, activities of factors VII and X and PIVKA-II concentrations did not reveal any difference between the two groups. At 2 weeks of age vitamin K, concentrations were raised compared with reported unsupplemented concentrations and no PIVKA-II was detectable. At 3 months vitamin K1 concentrations were back at unsupplemented values and PIVKA-II was detectable in 11.5% of infants. Therefore, a repeated oral prophylaxis will be necessary to completely prevent (biochemical) vitamin K deficiency beyond the age of 1 month.
Vitamin K deficiency is associated with haemorrhagic disease of the newborn. Three patterns of bleeding have been differentiated: early haemorrhagic disease of the newborn within 24 hours after birth, classical on days 1 to 7, and late after the first week of life.' Late disease is often intracranial. These haemorrhages may be fatal or cause serious morbidity. Breast feeding has an important role in the pathogenesis of classical and late disease.' Many countries recommend vitamin K prophylaxis after birth to prevent this hazard of vitamin K deficiency. Nevertheless, there are still controversies concerning the best way of providing effective prophylaxis, resulting in different policies. The safety of oral and parenteral vitamin K prophylaxis in the prevention of classical haemorrhagic disease of the newborn has been established, whereas the relationship between a single vitamin K dose at birth and late haemorrhagic disease of the newborn has not been clearly determined.' 2 Several studies have indicated that oral prophylaxis might be as effective as intramuscular administration, but these studies lack follow up beyond the first week of life. 5 Epidemiologically, intramuscular vitamin K prophylaxis appears to have a lower incidence of failure,68 probably because of the more reliable De Abreu, J M van Baal, K Motohara, absorption.4 Oral administration has the appealing characteristics that an injection is avoided and that administration is simple, resulting in better parental acceptance.
The aim of this study was to evaluate whether oral administration of vitamin K is as effective as intramuscular administration in the prevention of vitamin K deficiency beyond the first week of life in breast fed infants. Determination of proteins induced by vitamin K absence (PIVKA-II) was used to detect biochemical vitamin K deficiency. Vitamin PIVKA-II concentrations are expressed in arbitrary units (AU)/ml, so that 1 AU corresponds with 1 jig of purified prothrombin. In severe vitamin K deficiency PIVKA-II can amount to more than 20 AU/ml. The detection limit of 0-10 AU/ml was used as the upper normal limit, defining PIVKA-II concentrations higher or lower than that concentration as PIVKA-II positive or negative, respectively. Vitamin K, was extracted from 1 ml serum samples by a two step high performance liquid chromatographic (HPLC) procedure, according to the method of Lamber et al. ' 14 The reference range for neonates and infants is still unknown. Mean plasma concentrations in healthy breast fed infants of 1 month of age without vitamin K prophylaxis are reported to be 500-700 pg/ml.10 15 Formula fed infants have much higher concentrations of to 60% of infants were PIVKA-II positive if they were breast fed and had not received vitamin K prophylaxis at birth.'8 At the age of 1 month 12-3% were positive.'9 Biochemical vitamin K deficiency occurs frequently in unsupplemented breast fed infants. Widdershoven et al compared PIVKA-II concentrations in breast fed and formula fed infants. '0 At 4 days of age about 10% of both groups had PIVKA-II in their blood. At 1 month of age PIVKA-II was not detected in any formula fed infant, compared with in 5-5% of breast fed infants. At 3 months of age no formula fed infant was positive, compared with 7-5% of breast fed infants. Thus, formula feeding seems an effective way to prevent the appearance of PIVKA-II in the blood of young infants, probably due to the high intake of vitamin K,.
PIVKA-II was not detectable in any of our infants at 2 weeks of age. This corresponds with the raised vitamin K, concentrations in both groups. Surprisingly, in four 1 month old infants PIVKA-II was detected. However, the concentration in the only positive infant of the intramuscular group was at the limit of detection. So 24 Epidemiologically, intramuscular vitamin K prophylaxis appears to have a lower incidence of failure.8 In a recent survey in the British Isles, 27 cases of haemorrhagic disease of the newborn were recorded.8 Seven of them occurred in spite of oral vitamin K prophylaxis at birth. No failures were recorded after intramuscular administration, although there was uncertainty about intramuscular vitamin K in one case. The relative risk for babies who had received oral vitamin K compared with babies who had received intramuscular vitamin K was 13:1. The relative risk without prophylaxis was 81:1.8 A schedule of repeated oral doses was considered.25 Taking our results as well as epidemiological evidence into account, we suggest that for complete protection of breast fed infants against late haemorrhagic disease of the newborn, vitamin K administration should be repeated. Whether a monthly, weekly, or daily administered oral dose should be recommended deserves further investigation.
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